Physician profile
Manish Gupta
NPI 1528250966
$8,998.50
in general payments reported to CMS, 2019-2025
41 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,085 · 2020: $1,447 · 2021: $1,989 · 2022: $607 · 2023: $859 · 2024: $386 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,386.06 | 2019-2023 | Cardiomems |
| Cvrx, INC. | $1,102.13 | 2020-2023 | Barostim Neo System |
| Medtronic Vascular, INC. | $617.12 | 2019-2020 | |
| Amgen INC. | $524.87 | 2019-2025 | Repatha, Repatha |
| Inspire Medical Systems, INC. | $489.42 | 2020-2022 | |
| Abiomed | $473.62 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $425.17 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $401.21 | 2019-2024 | Lifevest |
| Penumbra, INC. | $374.32 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $355.86 | 2021-2025 | Verquvo |
| Bard Peripheral Vascular, INC. | $329.09 | 2019-2020 | |
| Boston Scientific Corporation | $275.33 | 2019-2023 | Wavewriter Alpha Prime 16, Varithena Administration Pack |
| Novo Nordisk INC | $264.56 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Kerecis Limited | $214.40 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Insulet Corporation | $185.70 | 2019 |
Show all 39 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.